A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.
作者信息
Phelan Maria, Cook Catherine
出版信息
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S5. doi: 10.1186/1471-2334-14-S6-S5. Epub 2014 Sep 19.
Abstract
摘要
相似文献
1
A treatment revolution for those who can afford it? Hepatitis C treatment: new medications, profits and patients.一场只为有支付能力者的治疗革命？丙型肝炎治疗：新药、利润与患者。
BMC Infect Dis. 2014;14 Suppl 6(Suppl 6):S5. doi: 10.1186/1471-2334-14-S6-S5. Epub 2014 Sep 19.
2
Elimination on the agenda for hepatitis C.丙型肝炎消除工作提上议程。
Lancet Infect Dis. 2014 Jun;14(6):452-3. doi: 10.1016/s1473-3099(14)70704-2.
3
Guideline: New HCV drugs should go to sickest patients.指南：新型丙肝药物应优先用于病情最严重的患者。
JAMA. 2014 Sep 17;312(11):1084-5. doi: 10.1001/jama.2014.11373.
4
China rejects patent on hepatitis C drug sofosbuvir.中国拒绝丙型肝炎药物索非布韦的专利。
BMJ. 2015 Jun 23;350:h3429. doi: 10.1136/bmj.h3429.
5
Screening urged for hepatitis C but drug costs are prohibitive.呼吁对丙型肝炎进行筛查，但药物成本过高。
CMAJ. 2014 Mar 18;186(5):329. doi: 10.1503/cmaj.109-4727. Epub 2014 Feb 18.
6
WHO issues guidelines on HCV amid drug cost controversy.在药物成本争议中，世界卫生组织发布了关于丙型肝炎病毒的指南。
JAMA. 2014 Jun 11;311(22):2262-3. doi: 10.1001/jama.2014.5277.
7
Medicine. Hepatitis C can be cured globally, but at what cost?医学。丙型肝炎在全球范围内都可以治愈，但代价是什么呢？
Science. 2014 Jul 11;345(6193):141-2. doi: 10.1126/science.1257737.
8
Campaigners challenge patent applications for hepatitis C drug in five countries.活动人士对五个国家的丙型肝炎药物专利申请提出质疑。
BMJ. 2015 Jun 1;350:h2938. doi: 10.1136/bmj.h2938.
9
Dare to refuse the exorbitant price of Sovaldi!敢于拒绝索华迪（Sovaldi）的高昂价格！
Prescrire Int. 2014 Nov;23(154):278.
10
US health insurers say Gilead hepatitis C drug too costly.美国医疗保险公司称吉利德公司的丙肝药物成本过高。
Clin Infect Dis. 2014 Jul 15;59(2):i-ii.
引用本文的文献
1
Hepatitis C-Everything a Primary Care Physician Needs to Know About Diagnosis, Management, and Follow-Up.丙型肝炎——基层医疗医生需要了解的关于诊断、管理及随访的一切。
J Clin Med. 2025 Jul 7;14(13):4801. doi: 10.3390/jcm14134801.
2
Variables affecting new drug prices in South Korea's pricing system.韩国定价体系中影响新药价格的变量。
Front Pharmacol. 2024 May 9;15:1370915. doi: 10.3389/fphar.2024.1370915. eCollection 2024.
3
Changes in Use of Hepatitis C Direct-Acting Antivirals After Access Restrictions Were Eased by State Medicaid Programs.国家医疗补助计划放宽对丙型肝炎直接作用抗病毒药物的使用限制后，其使用情况发生变化。
JAMA Health Forum. 2024 Apr 5;5(4):e240302. doi: 10.1001/jamahealthforum.2024.0302.
4
Predicting Treatment Failure for Initiators of Hepatitis C Virus Treatment in the era of Direct-Acting Antiviral Therapy.在直接抗病毒治疗时代预测丙型肝炎病毒治疗初治患者的治疗失败情况。
Front Pharmacol. 2020 Nov 13;11:551500. doi: 10.3389/fphar.2020.551500. eCollection 2020.
5
Barriers for Access to New Medicines: Searching for the Balance Between Rising Costs and Limited Budgets.获取新药的障碍：探寻成本上升与预算有限之间的平衡
Front Public Health. 2018 Dec 5;6:328. doi: 10.3389/fpubh.2018.00328. eCollection 2018.
6
Tackling HCV-3 in Asia: Breakthroughs for Efficient and Cost-effective Treatment Strategies.应对亚洲的丙型肝炎病毒-3型：高效且具成本效益的治疗策略的突破
Euroasian J Hepatogastroenterol. 2016 Jan-Jun;6(1):35-42. doi: 10.5005/jp-journals-10018-1163. Epub 2016 Jul 9.
7
Comprehensive taxonomy and worldwide trends in pharmaceutical policies in relation to country income status.与国家收入状况相关的制药政策的综合分类及全球趋势。
BMC Health Serv Res. 2017 May 25;17(1):371. doi: 10.1186/s12913-017-2304-2.
8
Treatment optimization for HIV/HCV co-infected patients.艾滋病毒/丙型肝炎病毒合并感染患者的治疗优化
Ther Adv Infect Dis. 2017 Jan;4(1):18-36. doi: 10.1177/2049936116681279. Epub 2016 Dec 9.
9
Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia) in Brazil; Implications for Future Pricing Considerations.巴西消费者对登革热疫苗（CYD-TDV，登瓦夏）的支付意愿；对未来定价考量的启示
Front Pharmacol. 2017 Feb 2;8:41. doi: 10.3389/fphar.2017.00041. eCollection 2017.
10
Payers' Views of the Changes Arising through the Possible Adoption of Adaptive Pathways.支付方对可能采用适应性路径所带来变化的看法。
Front Pharmacol. 2016 Sep 28;7:305. doi: 10.3389/fphar.2016.00305. eCollection 2016.
本文引用的文献
1
Hepatitis C in the Eastern Mediterranean Region.东地中海区域的丙型肝炎
East Mediterr Health J. 2013 Jul;19(7):587-8.
2
Hepatitis C treatment access and uptake for people who inject drugs: a review mapping the role of social factors.丙型肝炎治疗的可及性和接受度：社会因素作用的映射综述
Harm Reduct J. 2013 May 7;10:7. doi: 10.1186/1477-7517-10-7.
3
UNITAID can address HCV/HIV co-infection.国际药品采购机制能够应对丙型肝炎病毒/艾滋病病毒合并感染问题。
Lancet. 2013 Feb 23;381(9867):628. doi: 10.1016/S0140-6736(13)60346-3.
4
Determinants of hepatitis C virus treatment completion and efficacy in drug users assessed by meta-analysis.通过荟萃分析评估吸毒者丙型肝炎病毒治疗完成和疗效的决定因素。
Clin Infect Dis. 2013 Mar;56(6):806-16. doi: 10.1093/cid/cis1007. Epub 2012 Dec 7.
5
Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence.全球丙型肝炎病毒感染的流行病学：特定年龄组丙型肝炎病毒抗体血清流行率的新估计。
Hepatology. 2013 Apr;57(4):1333-42. doi: 10.1002/hep.26141. Epub 2013 Feb 4.
6
Global epidemiology of hepatitis B and hepatitis C in people who inject drugs: results of systematic reviews.全球注射吸毒人群乙型肝炎和丙型肝炎的流行病学：系统评价结果。
Lancet. 2011 Aug 13;378(9791):571-83. doi: 10.1016/S0140-6736(11)61097-0. Epub 2011 Jul 27.
7
HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage.HIV 预防、治疗和关爱服务在注射毒品人群中的应用：全球、地区和国家覆盖范围的系统评价。
Lancet. 2010 Mar 20;375(9719):1014-28. doi: 10.1016/S0140-6736(10)60232-2. Epub 2010 Feb 26.
8
Viral hepatitis and HIV co-infection.病毒性肝炎与 HIV 合并感染。
Antiviral Res. 2010 Jan;85(1):303-15. doi: 10.1016/j.antiviral.2009.10.021. Epub 2009 Nov 1.
9
Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons.在HIV感染者的丙型肝炎病毒（HCV）治疗期间，使用齐多夫定而非基于体重的利巴韦林给药会影响贫血情况。
J Viral Hepat. 2006 Oct;13(10):683-9. doi: 10.1111/j.1365-2893.2006.00749.x.
Zotero 插件